213 related articles for article (PubMed ID: 31609178)
41. The Timing of Radical Cystectomy for bacillus Calmette-Guérin Failure: Comparison of Outcomes and Risk Factors for Prognosis.
Haas CR; Barlow LJ; Badalato GM; DeCastro GJ; Benson MC; McKiernan JM
J Urol; 2016 Jun; 195(6):1704-9. PubMed ID: 26807928
[TBL] [Abstract][Full Text] [Related]
42. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
Martínez-Piñeiro L; Portillo JA; Fernández JM; Zabala JA; Cadierno I; Moyano JL; Solsona E; Unda M; Beardo P; Rodríguez-Molina J; Chantada V; Palou J; Muntañola P; Alonso Dorrego JM; Pérez-Garcia FJ; Silva JM; Chesa N; Montesinos M; Ojea A; Madero R; Martínez-Piñeiro JA
Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457
[TBL] [Abstract][Full Text] [Related]
43. The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Guérin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data.
Liem EIML; Oddens JR; Vernooij RWM; Li R; Kamat A; Dinney CP; Mengual L; Alcaraz A; Izquierdo L; Savic S; Thalmann GN; Bubendorf L; Sylvester RJ; de Reijke TM
J Urol; 2020 Feb; 203(2):283-291. PubMed ID: 31549936
[TBL] [Abstract][Full Text] [Related]
44. Stratifying risk for multiple, recurrent, and large (≥3 cm) Ta, G1/G2 tumors in non-muscle-invasive bladder cancer.
Suh J; Jung JH; Kwak C; Kim HH; Ku JH
Investig Clin Urol; 2021 Jul; 62(4):408-415. PubMed ID: 34190435
[TBL] [Abstract][Full Text] [Related]
45. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.
Nakai Y; Anai S; Tanaka N; Chihara Y; Haramoto M; Otani T; Nakagawa Y; Hirao Y; Konishi N; Fujimoto K
Int J Urol; 2016 Oct; 23(10):854-860. PubMed ID: 27416975
[TBL] [Abstract][Full Text] [Related]
46. Cost-Effectiveness of Maintenance bacillus Calmette-Guérin for Intermediate and High Risk Nonmuscle Invasive Bladder Cancer.
Sharma V; Wymer KM; Borah BJ; Saigal CS; Litwin MS; Packiam VT; Thompson RH; Tollefson MK; Karnes RJ; Boorjian SA
J Urol; 2020 Sep; 204(3):442-449. PubMed ID: 32191580
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin.
Morales A; Herr H; Steinberg G; Given R; Cohen Z; Amrhein J; Kamat AM
J Urol; 2015 Apr; 193(4):1135-43. PubMed ID: 25286009
[TBL] [Abstract][Full Text] [Related]
48. Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer.
Thiel T; Ryk C; Renström-Koskela L; Steineck G; Schumacher MC; Wiklund NP; de Verdier PJ
World J Urol; 2019 Jan; 37(1):155-163. PubMed ID: 29905887
[TBL] [Abstract][Full Text] [Related]
49. Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: Long-term follow-up experience at a single institute.
Miyake M; Gotoh D; Shimada K; Tatsumi Y; Nakai Y; Anai S; Torimoto K; Aoki K; Tanaka N; Konishi N; Fujimoto K
Int J Urol; 2015 Jun; 22(6):541-7. PubMed ID: 25857336
[TBL] [Abstract][Full Text] [Related]
50. Characterizing intermediate-risk non-muscle-invasive bladder cancer: Implications for the definition of intermediate risk and treatment strategy.
Matsumoto K; Kikuchi E; Yanai Y; Hayakawa N; Ito Y; Maeda T; Nagata H; Miyajima A; Oya M
Urol Oncol; 2017 May; 35(5):208-214. PubMed ID: 28065394
[TBL] [Abstract][Full Text] [Related]
51. The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer: time to change treatment paradigm?
Thomas F; Rosario DJ; Rubin N; Goepel JR; Abbod MF; Catto JW
Cancer; 2012 Nov; 118(22):5525-34. PubMed ID: 22544645
[TBL] [Abstract][Full Text] [Related]
52. Low-risk non-muscle-invasive bladder cancer: Further prognostic stratification into the "very-low-risk" group based on tumor size.
Lee A; Lee HJ; Huang HH; Ho H; Chen K
Int J Urol; 2019 Apr; 26(4):481-486. PubMed ID: 30834632
[TBL] [Abstract][Full Text] [Related]
53. EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification.
Wang H; Ding W; Jiang G; Gou Y; Sun C; Chen Z; Xu K; Xia G
Medicine (Baltimore); 2018 Sep; 97(36):e12006. PubMed ID: 30200080
[TBL] [Abstract][Full Text] [Related]
54. Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer: how much is enough?
Decobert M; LaRue H; Harel F; Meyer F; Fradet Y; Lacombe L
Cancer; 2008 Aug; 113(4):710-6. PubMed ID: 18543328
[TBL] [Abstract][Full Text] [Related]
55. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
56. Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-muscle Invasive Bladder Cancer in Asia.
Ieda T; Muto S; Shimizu F; Taguri M; Yanada S; Kitamura K; Terai K; Saito K; Ogishima T; Nagata M; Ide H; Okegawa T; Wakumoto Y; Sakamoto Y; Tsujimura A; Yamaguchi R; Nutahara K; Horie S
EBioMedicine; 2016 Oct; 12():98-104. PubMed ID: 27614395
[TBL] [Abstract][Full Text] [Related]
57. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
58. Diminished efficacy of Bacille Calmette-Guérin among elderly patients with nonmuscle invasive bladder cancer.
Margel D; Alkhateeb SS; Finelli A; Fleshner N
Urology; 2011 Oct; 78(4):848-54. PubMed ID: 21840578
[TBL] [Abstract][Full Text] [Related]
59. Should intravesical Bacillus Calmette-Guerin (BCG) treatment be administered to patients with T0 after repeat transurethral resection of bladder tumor in patients with high-risk non-muscle invasive bladder cancer?
Yuk HD; Jeong CW; Kwak C; Kim HH; Ku JH
PLoS One; 2018; 13(11):e0208267. PubMed ID: 30496283
[TBL] [Abstract][Full Text] [Related]
60. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
